Antimicrobial resistance profile of Pseudomonas aeruginosa strains
DOI:
https://doi.org/10.52556/2587-3873.2024.4(101).10Keywords:
pseudomonas, Antibiotics, resistanceAbstract
Antimicrobial resistance is one of the most serious threats facing humanity today. Th e majority of pathogens on the WHO list with high resistance to antibiotics are Gram-negative bacteria, including Pseudomonas. Data on the etiological structure of septico-purulent infections (SPIs), multiple antibiotic resistance of microorganisms isolated from patients hospitalized at the Institute of Emergency Medicine were analyzed. Gram-positive bacteria accounted for 40,15% among the isolated strains, with a predominance of Enterococcus faecalis, Staphylococcus aureus and Staphylococcus epidermidis species. Gram-negative bacteria constituted 56,34%, the most prevalent being Klebsiella pneumoniae, Pseudomonas aeruginosa and Escherichia coli. P. aeruginosa had the highest rate of MDR – 92,71%, followed by Acinetobacter spp. followed by Acinetobacter spp., E. faecium and K. pneumoniae. XDR prevalence was highest in P. aeruginosa (81,50%), Acinetobacter spp., K. pneumoniae and E. faecium. PDR rates were high in strains of K. pneumoniae, E. faecium, P. aeruginosa and Acinetobacter spp. P. aeruginosa showed increased resistance to penicillin’s, beta-lactams with inhibitors and third/ fourth generation cephalosporins. Extremely high resistance was also observed to Imipenem, Meropenem and fl uoroquinolone. Moderate resistance was observed to aminoglycosides, while sensitivity was high to Colistin and Polymyxin B. P. aeruginosa strains from intensive care and reanimation (ICU) wards showed very high resistance to various antibiotics. Isolates from septic surgery and trauma wards also showed increased antibiotic resistance.
References
1. Breijyeh Z., Jubeh B., Karaman R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. In: Molecules, 2020, no.6, vol. 25. https://doi.org/10.3390/molecules25061340
2. Pérez J., Contreras-Moreno F.J., Marcos-Torres. et al. The antibiotic crisis: How bacterial predators can help. In: Computational and Structural Biotechnology Journal. 2020, vol. 18, pp. 2547-2555. https://doi.org/10.1016/j.csbj.2020.09.010
3. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis [Internet]. World Health Organization [cited 2024 Jun 29]. Available from: https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12
4. Moore. E.R.B., Tindall. B.J., Martins. et al. Nonmedical: Pseudomonas. In: The Prokaryotes. 2006; pp. 646-703. https://doi.org/10.1007/0-387-30746-X_21
5. Hancock. R.E.W., Speert. D.P. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. In: Drug Resistance Updates. 2000, Vol. 3, nr. 4, p. 247-255. https://doi.org/10.1054/drup.2000.0152
6. Pang Z., Raudonis R., Glick B.R, Lin T.J et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. In: Biotechnology Advances. 2019, Vol. 37, nr. 1, p. 177-192. https://doi.org/10.1016/j.biotechadv.2018.11.013
7. Morrison A.J, Wenzel R.P. Epidemiology of infections due to Pseudomonas aeruginosa. In: Reviews of infectious diseases. 1984, Vol. 6, Suppl 3. https://doi.org/10.1093/clinids/6.Supplement_3.S627
8. Magill S.S., Edwards J.R., Bamberg et al. Multistate Point-Prevalence Survey of Health Care-Associated Infections. In: The New England journal of medicine. 2014, Vol. 370, no. 13, p. 1198. https://doi.org/10.1056/NEJMoa1306801
9. Weiner L.M., Webb A.K., Limbago et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. In: Infection control and hospital epidemiology. NIH Public Access, 2016, Vol. 37, nr. 11, p. 1288. https://doi.org/10.1017/ice.2016.174
10. Williams B.J., Dehnbostel J., Blackwell T.S. Pseudomonas aeruginosa: host defence in lung diseases. In: Respirology. 2010 Vol. 15, no. 7, pp. 1037-1056. https://doi.org/10.1111/j.1440-1843.2010.01819.x
11. Parker C.M., Kutsogiannis J., Muscedere J. et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. In: Journal of critical care. 2008, Vol. 23, no. 1, pp. 18-26. https://doi.org/10.1016/j.jcrc.2008.02.001
12. Vincent J.L., Sakr Y., Singer M. et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. In: The Journal of the American Medical Association. 2020, Vol. 323, no. 15, p. 1478. https://doi.org/10.1001/jama.2020.2717
13. Kalil A.C., Metersky M.L., Klompas et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of Americaand the American Thoracic Society. In: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2016, Vol. 63, no. 5, p. e61. https://doi.org/10.1093/cid/ciw353
14. Fujitani S., Sun H.Y., Yu V.L., Weingarten J.A. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. In: Chest. 2011, Vol. 139, no. 4, pp. 909-919. https://doi.org/10.1378/chest.10-0166
15. Micek ST.t., Reichley R.M., Kollef M.H.. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. In: Medicine. 2011, Vol. 90, no. 6, pp. 390-395. https://doi.org/10.1097/MD.0b013e318239cf0a
16. Planquette B, Timsit J.F., Misset et al. Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure. In: American journal of respiratory and critical care medicine. 2013, Vol. 188, no. 1, pp. 69-76. https://doi.org/10.1164/rccm.201210-1897OC
17. Trouillet J.L., Vuagnat A., Combes et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002, Vol. 34, no. 8, pp. 1047-1054. https://doi.org/10.1086/339488
18. Micek S.T, Kollef M.H., Torres A. et al. Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification. In: Infection control and hospital epidemiology. 2015, Vol. 36, no. 10, pp. 1190-1197. https://doi.org/10.1017/ice.2015.167
19. Mittal R., Aggarwal S., Sharma S., Chhibber S. et al. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. In: Journal of infection and public health. 2009, Vol. 2, no. 3, pp. 101-111. https://doi.org/10.1016/j.jiph.2009.08.003
20. Rosenthal V.D., Al-Abdely H.M., El-Kholy A.A. et al. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module. In: American journal of infection control. 2016, Vol. 44, no. 12, pp. 1495-1504.
21. Kitagawa K., Shigemura K., Yamamichi F. et al. Bacteremia complicating urinary tract infection by Pseudomonas aeruginosa: Mortality risk factors. In: International journal of urology: official journal of the Japanese Urological Association. 2019, Vol. 26, no. 3, pp. 358-362. https://doi.org/10.1111/iju.13872
22. Multidrug-resistant Pseudomonas aeruginosa | A.R. & Patient Safety Portal [Internet]. [cited 2024 Jul 7]. Available from: https://arpsp.cdc.gov/profile/antibiotic-resistance/mdr-pseudomonas-aeruginosa?redirect=true
23. Weiner-Lastinger L.M., Abner S. et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. In: Infection control and hospital epidemiology. 2020, Vol. 41, no. 1, p. 1. https://doi.org/10.1017/ice.2019.296
24. Walters M.S., Grass J.E., Bulens et al. Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015. In: Emerging Infectious Diseases. 2019, Vol. 25, no. 7, p. 1281. https://doi.org/10.3201/eid2507.181200
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
